Praxis Precision Medicines Inc ( PRAX ). stock skyrocketed on Thursday.

PRAX is reaching significant price levels. Check the market position here.

The clinical-stage biopharmaceutical company released topline results for the Phase 3 Essential3 program of ulixacaltamide in essential tremor (ET).

Essential tremor is a neurological disorder that causes involuntary, rhythmic shaking, most commonly in the hands and arms during movement, but it can also affect the head, voice, or legs.

Also Read: Praxis’ Epilepsy Treatment Shows Promise With Decreased Seizures

Study 1: Placebo-controlled Parallel Group Study Topline Efficacy Results

Study 1 showed a statistically significant and clinically meaningful 4.3 point mean improvement in the mADL11 score at Week 8 (p